1. Home
  2. IBRX vs CRL Comparison

IBRX vs CRL Comparison

Compare IBRX & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$7.59

Market Cap

8.4B

Sector

Health Care

ML Signal

HOLD

Logo Charles River Laboratories International Inc.

CRL

Charles River Laboratories International Inc.

HOLD

Current Price

$171.42

Market Cap

7.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IBRX
CRL
Founded
2014
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Commercial Physical & Biological Resarch
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.4B
7.5B
IPO Year
2015
1999

Fundamental Metrics

Financial Performance
Metric
IBRX
CRL
Price
$7.59
$171.42
Analyst Decision
Strong Buy
Buy
Analyst Count
7
12
Target Price
$12.57
$200.09
AVG Volume (30 Days)
24.1M
718.8K
Earning Date
05-11-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
38.71
N/A
EPS
N/A
N/A
Revenue
$113,288,000.00
$1,857,601,000.00
Revenue This Year
$88.59
$0.99
Revenue Next Year
$131.15
$3.26
P/E Ratio
N/A
N/A
Revenue Growth
668.31
10.48
52 Week Low
$1.83
$91.86
52 Week High
$12.43
$228.88

Technical Indicators

Market Signals
Indicator
IBRX
CRL
Relative Strength Index (RSI) 48.47 54.49
Support Level $2.25 $146.49
Resistance Level $8.28 $182.76
Average True Range (ATR) 0.93 7.21
MACD -0.24 2.02
Stochastic Oscillator 39.00 99.98

Price Performance

Historical Comparison
IBRX
CRL

About IBRX ImmunityBio Inc.

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

About CRL Charles River Laboratories International Inc.

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Share on Social Networks: